# SenesTech, Inc.: Form 10-Q/A for the period ended Jun 30, 2017

- Company: [SenesTech, Inc.](/companies/snes.md) (CIK 1680378)
- Form: 10-Q/A
- Filed: 2017-11-07
- Accepted by EDGAR: Nov 6, 2017, 17:32 ET
- Period: 2017-06-30
- Accession: 0001615774-17-006279
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1680378/000161577417006279/s107998_10qa.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1680378/000161577417006279/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 3 months, 2017-04-01 to 2017-06-30 | $12.0k | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months, 2017-01-01 to 2017-06-30 | $16.0k | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2017-04-01 to 2017-06-30 | −$2.0k | us-gaap:GrossProfit |
| Gross profit | 6 months, 2017-01-01 to 2017-06-30 | $1.0k | us-gaap:GrossProfit |
| Research and development | 3 months, 2017-04-01 to 2017-06-30 | $973.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2017-01-01 to 2017-06-30 | $1.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2017-04-01 to 2017-06-30 | −$3.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2017-01-01 to 2017-06-30 | −$7.1m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2017-04-01 to 2017-06-30 | −$3.6m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2017-01-01 to 2017-06-30 | −$7.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-04-01 to 2017-06-30 | −$0.35 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2017-01-01 to 2017-06-30 | −$0.69 | us-gaap:EarningsPerShareBasicAndDiluted |
| Capital expenditure | 6 months, 2017-01-01 to 2017-06-30 | $863.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2017-06-30 | $2.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-06-30 | $6.4m | us-gaap:AssetsCurrent |
| Total assets | at 2017-06-30 | $8.0m | us-gaap:Assets |
| Current liabilities | at 2017-06-30 | $1.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-06-30 | $2.3m | us-gaap:Liabilities |
| Long-term debt | at 2017-06-30 | $642.0k | us-gaap:LongTermDebt |
| Current portion of debt | at 2017-06-30 | $160.0k | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2017-06-30 | $160.0k | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2017-06-30 | $5.7m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 39,941 characters.

As used in this Quarterly Report on Form 10-Q, “we,” “us,” “our” and “the Company” refer to SenesTech, Inc., a Delaware corporation.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our condensed consolidated financial statements and related notes. Some statements and information contained in this Management’s Discussion and Analysis of Financial Condition and Results of Operations are not historical facts but are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, readers can identify forward- loking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “intend,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” or the negative of these terms or other comparable terminology, which when used are meant to signify the statement as forward-looking. These forward-looking statements include, but are not limited to, statements about our plans, objectives, expectations and intentions and other statements that are not historical facts. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and situations that are difficult to predict and that may cause our own, or our industry’s actual results, to be materially different from the future results that are expressed or implied by these statements. Accordingly, actual results may differ materially from those anticipated or expressed in such statements as a result of a variety of factors, including those discussed in Item 1A of Part I of our Annual Report on Form 10-K for the year ended December 31, 2016, as amended, entitled “Risk Factors,” and those contained from time to time in our other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

All amounts shown in the following Management’s Discussion and Analysis of Financial Condition and Results of Operations are full amounts (and are not shown in thousands).

### Overview

Since our inception in 2004, we have devoted substantially all of our resources to organizing and staffing our company, conducting research and development activities for our product candidates, business planning, raising capital and acquiring and developing product and technology rights. Until August 2016, we did not have any products approved for sale, and we have not generated any significant revenue from product sales to date. We have funded our operations to date with proceeds from the sale of common stock and preferred stock, the issuance of convertible and other promissory notes and, to a lesser extent, payments received in connection with research grants and licensing fees. Through June 30, 2017, we had received net proceeds of $42.2 million from our sales of common stock, preferred stock and issuance of convertible and other promissory notes and an aggregate of $1.6 million from research grants and licensing fees.

We have incurred significant operating losses since our inception. Our net losses were $3.6 million, $7.0 million and $11.0 million for the three and six months ended June 30, 2017 and the year ended December 31, 2016, respectively. As of June 30, 2017, we had an accumulated deficit of $68.4 million. We expect to continue to incur significant expenses and generate operating losses for at least the next 12 months.

We have historically utilized, and intend to continue to utilize, various forms of stock-based awards in order to hire, retain and motivate talented employees, consultants and directors and encourage them to devote their best efforts to our business and financial success. In addition, we believe that our ability to grant stock-based awards is a valuable and necessary compensation tool that aligns the long-term financial interests of our employees, consultants and directors with the financial interests of our stockholders.

As a result, a significant portion of our operating expenses includes stock-based compensation expense. Stock-based compensation expense has been, and will continue to be for the foreseeable future, a significant recurring expense in our business and an important part of our compensation strategy. Specifically, our stock-based compensation expense for each of the six months ended June 30, 2017 and June 30, 2016 was $1.9 million and $1.5 million, respectively, which represented 26.5% and 33.0%, respectively, of our total operating expenses for those periods.

### Components of our Results of Operations

### Revenue

To date, we have generated less than $25,000, from product sales, but we do expect to generate revenue from the sale of products or royalties beginning in the second half of 2017. Except for the minimal product sales noted above, all of our revenue to date has been derived from payments received in connection with research grants and licensing fees received as a result of our execution of the former license agreement with Neogen.

We recognized product sales revenue of $10,000 and $0 for the three months ended June 30, 2017 and 2016, respectively, and $17,000 and $0 and for the six months ended June 30, 2017 and 2016, respectively. In addition, for the six months ended June 30, 2016, we recognized revenue of $93,000 under our former license agreement with Neogen and $37,000 under NIH grants. We do not anticipate additional grant revenue under the NIH grants or additional revenue from our former license agreement with Neogen.

### Operating Expenses

#### Research and Development Expenses

Research and development expenses consist primarily of costs incurred in connection with the discovery and development of our product candidates, which include:

- Employee-related expenses, including salaries, related benefits, travel and stock-based compensation expense for employees engaged in research and development functions;
- Expenses incurred in connection with the development of our product candidates; and
- Facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and supplies.

We expense research and development costs as incurred.

At this time, we cannot reasonably estimate the costs for completing the development of ContraPest or the cost associated with the development of any of our other product candidates.

We plan to continue to hire employees to support our research and development efforts and anticipate that we will continue to utilize various forms of stock-based compensation awards in order to attract and retain employees for our research and development efforts. As a result, we anticipate that stock-based compensation expense will continue to represent a significant portion of our research and development expenses for the foreseeable future.

#### General and Administrative Expenses

General and administrative expenses consist primarily of salaries and related costs, including stock-based compensation, for personnel in executive, finance and administrative functions. General and administrative expenses also include direct and allocated facility-related costs as well as professional fees for legal, consulting, accounting and audit services.

We anticipate that our general and administrative expenses may increase in the future as we increase our headcount to support commercialization of any approved products and further development of our product candidates. We also anticipate that we will incur increased accounting, audit, legal, regulatory, compliance, director and officer insurance costs as well as investor and public relations expenses associated with being a public company.

We plan to continue to hire employees to support our commercialization of any approved products and further development of our product candidates, and anticipate that we will continue to utilize various forms of stock-based compensation awards in order to attract and retain qualified employees. As a result, we anticipate that stock-based compensation expense will continue to represent a significant portion of our general and administrative expenses for the foreseeable future.

#### Other Income (Expense), Net

*Interest Income*. Interest income consists primarily of interest income earned on cash and cash equivalents. Our interest income has not been significant due to nominal cash and investment balances and low interest earned on invested balances.

*Interest Expense*. Interest expense consists of interest accrued on $2.9 million in convertible and other promissory notes we issued during 2014, 2015 and 2016, most of which was converted or redeemed by December 31, 2016.

*Other Income (Expense), Net*. Other income (expense), net; consists primarily of net losses on extinguishment of convertible and non-convertible, secured and unsecured promissory notes.

#### Income Taxes

Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our earned research and development tax credits, due to our uncertainty of realizing a benefit from those items. As of December 31, 2016, we had federal and state net operating loss carryforwards of $34.0 million and $27.8 million, respectively, which begin to expire in 2021 and 2016, respectively, unless previously utilized.

### Comparison of the Three and Six Months Ended June 30, 2017 and 2016

The following table summarizes our results of operations for the three and six months ended June 30, 2017 and 2016:

### SENESTECH, INC.

### CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

### (In thousands, except shares and per share data)

### (Unaudited)

| Revenue: | For the Three Months Ended June 30, 2017 | 2016 | For the Six Months Ended June 30, 2017 | 2016 |
| --- | ---: | ---: | ---: | ---: |
| License revenue | $— | $84 | $— | $130 |
| Sales | 10 | — | 17 | — |
| Total revenue | 10 | 84 | 17 | 130 |
| Cost of sales | 12 | — | 16 | — |
| Gross profit | (2) | 84 | 1 | 130 |
| Operating expenses: |  |  |  |  |
| Research and development | 973 | 665 | 1,796 | 1,135 |
| General and administrative | 2,632 | 1,352 | 5,271 | 3,327 |
| Total operating expenses | 3,605 | 2,017 | 7,067 | 4,462 |
| Net operating loss | (3,607) | (1,933) | (7,066) | (4,332) |
| Other income (expense): |  |  |  |  |
| Interest income | 1 | — | 11 | — |
| Interest expense | (8) | (12) | (21) | (43) |
| Interest expense, related parties | — | (17) | (1) | (34) |
| Loss on extinguishment of unsecured promissory note | — | (103) | — | (112) |
| Other income (expense) | 31 | 83 | 39 | 51 |
| Total other income (expense) | 24 | (49) | 28 | (138) |
| Net loss | (3,583) | (1,982) | (7,038) | (4,470) |
| Series A convertible preferred stock dividends | — | (30) | — | (60) |
| Net loss and comprehensive loss | $(3,583) | $(2,012) | $(7,038) | $(4,530) |

#### Three Months Ended June 30, 2017 compared to Three Months Ended June 30, 2016

#### Revenue

Revenue was $10,000 for the three months ended June 30, 2017, compared to $84,000 for three months ended June 30, 2016.

The $10,000 revenue recognized for the three months ended June 30, 2017 represented sales of our product, ContraPest. The $84,000 of revenue for the three months ended June 30, 2016, was earned from research grants and from our former license agreement with Neogen, which was terminated in January 2017. We did not recognize any license fees in 2017 under this agreement.

#### Cost of Sales

Cost of sales was $12,000 for the three months ended June 30, 2017, compared to $0 for three months ended June 30, 2016. The increase in cost of sales corresponded to the product launch of ContraPest. Cost of sales exceeded sales for the period due to manufacturing inefficiencies surrounding the start-up of the new manufacturing line and the cost of replacement product shipped to replace damaged product.

#### Research and Development Expenses

*(in thousands)*

| Direct research and development expenses: Unallocated expenses: | Three Months Ended June 30, 2017 | 2016 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Personnel related (including stock-based compensation) | $420 | $360 | $60 |
| Professional Fees/Consultants | 197 | 12 | 185 |
| Facility related | 74 | 57 | 17 |
| Other | 282 | 236 | 46 |
| Total research and development expenses | $973 | $665 | $308 |

Research and development expenses were $973,000 for the three months ended June 30, 2017, compared to $665,000 for the same period in 2016. The $308,000 increase in research and development expenses was primarily due to an increase of $60,000 in personnel-related costs. This increase in personnel-related costs resulted from increased research and development salaries of $57,000 due to headcount additions in 2017 and an increase in stock-based compensation expense of $3,000. Professional services and consulting expenses increased $185,000 for the three months ended June 30, 2017, compared to the same period in 2016 primarily due to an increase in synthetic triptolide research fees and legal fees. Rent and utilities for the three months ended June 30, 2017 increased $17,000 over the same period in 2016 due to the expansion into the research space at Northern Arizona Center for Entrepreneurship and Technology (“NACET”) facility. Other expenses increased by $46,000 from $282,000 for the three month s ended June 30, 2017 as compared to the same period in 2016, primarily due to increased state registration and filing fees increased travel expenses related to field team support due to on-site evaluations of potential customers and research operations and increased depreciation expense due to fixed asset additions in our research operations. We have now filed in all 50 states and the District of Columbia and have begun the process of refiling in some states.

We continue to investigate applications of our core technology to other product candidates, which includes laboratory tests and academic collaborations. We also continue to develop our supply chain, particularly identifying and improving our sourcing of triptolide, a key active ingredient for our product candidates.

#### General and Administrative Expenses

General and administrative expenses were $2.6 million for the three months ended June 30, 2017, compared to $1.4 million for the three months ended June 30, 2016. The increase of $1.2 million in general and administrative expenses was due to an increase of $1.0 million in personnel related expenses, and increase of $140,000 in professional services fees, a $36,000 increase in office supplies and non-capitalized furniture and computer equipment, offset by lower travel expenses of $30,000. The increase in personnel related expenses consisted of an increase in stock based compensation of $466,000 and an increase of $500,000 in net additional salary costs. The increase of $140,000 in professional service fees for the three month period ended June 30, 2017 as compared to the same period in 2016 is primarily related to an increase in Board related fees and expenses of $104,000, an increase in legal fees of $48,000, and an increase of $36,000 in shareholder relations and general consulting, offset by lower accounting and audit fees of $48,000.

#### Interest Expense

We recorded $7,000 of interest expense, net for the three months ended June 30, 2017, compared to $29,000 for the same period in 2016. The decrease in interest expense of $22,000 was the result of a decrease of $2.9 million in convertible notes that were issued in 2014 and exchanged for Series B convertible preferred stock in December of 2016.

#### Other Income (Expense), Net

We recorded $31,000 of other income, net for the three months ended June 30, 2017, compared to $20,000 of other expense for the same period in 2016. The $51,000 net decrease in other expense was primarily due to the expense related to the year-over-year fair market value adjustment of our convertible promissory notes.

### Six Months Ended June 30, 2017 compared to Six Months Ended June 30, 2016

#### Revenue

Revenue was $17,000 for the six months ended June 30, 2017, compared to $130,000 for six months ended June 30, 2016.

The $17,000 revenue recognized for the six months ended June 30, 2017 represented sales of our product, ContraPest. The $130,000 of revenue for the six months ended June 30, 2016 was earned from research grants and from our former license agreement with Neogen, which was terminated in January 2017. We did not recognize any license fees in 2017 under this agreement.

#### Cost of Sales

Cost of sales was $16,000 for the six months ended June 30, 2017, compared to $0 for six months ended June 30, 2016. The increase in cost of sales corresponded to the product launch of ContraPest. Cost of sales for the period were almost 100% of sales due to manufacturing inefficiencies surrounding the start-up of the new manufacturing line and the cost of replacement product shipped to replace damaged product.

#### Research and Development Expenses

*(in thousands)*

| Direct research and development expenses: Unallocated expenses: | Six Months Ended June 30, 2017 | 2016 | Increase (Decrease) |
| --- | ---: | ---: | ---: |
| Personnel related (including stock-based compensation) | $839 | $682 | $157 |
| Professional Fees/Consultants | 233 | 132 | 101 |
| Facility related | 152 | 106 | 46 |
| Other | 572 | 215 | 357 |
| Total research and development expenses | $1,796 | $1,135 | $661 |

Research and development expenses were $1.8 million for the six months ended June 30, 2017, compared to $1.1 million for the same period in 2016. The $700,000 increase in research and development expenses was primarily due to an increase of $157,000 in personnel-related costs. This increase in personnel-related costs resulted from increased research and development salaries of $147,000 due to headcount additions in 2017 and an increase in stock-based compensation expense of $10,000. Professional services and consulting expenses increased $101,000 for the six months ended June 30, 2017 compared to the same period in 2016 primarily due to an increase in synthetic triptolide research fees and legal fees. State registration and filing fees increased $85,000 for the six months ended June 30, 2017 compared to the same period in 2016 due to the increase in state filings and registrations as we have now filed in all 50 states and the District of Columbia and have begun the process of refiling in some states. Travel expenses related to field team support increased $162,000 for six months ended June 30, 2017 over the same period in 2016 due to on-site evaluations of potential customers and research operations. Rent and utilities for the six months ended June 30, 2017 increased $46,000 over the same period in 2016 due to the expansion into the research space at our NACET facility. Depreciation expense increased $22,000 for the three months ended June 30, 2017 over the same period in 2016 due to fixed asset additions in our research operations.

We continue to investigate applications of our core technology to other product candidates, which includes laboratory tests and academic collaborations. We also continue to develop our supply chain, particularly identifying and improving our sourcing of triptolide, a key active ingredient for our product candidates.

#### General and Administrative Expenses

General and administrative expenses were $5.3 million for the six months ended June 30, 2017, compared to $3.3 million for the six months ended June 30, 2016. The increase of $2.0 million in general and administrative expenses was due to an increase of $1.5 million in personnel related expenses, an increase in travel expenses of $135,000, , an increase in insurance expense of $170,000, an increase of $88,000 in professional services fees, a $65,000 increase in office supplies and non-capitalized furniture and computer equipment, an increase in depreciation expense of $39,000 and an increase in stock service and shareholder relations expenses of $28,000. The increase in personnel related expenses consisted of an increase in stock based compensation of $389,000 and an increase of $1.1 million in net additional salary costs. The increase of $88,000 in professional service fees for the six month period ended June 30, 2017 as compared to the same period in 2016 is primarily related to an increase in Board related fees and expenses of $233,000 offset by a decrease in accounting and audit fees of $145,000. The increase in depreciation expense for the six month period ended June 30, 2017 over the same period in 2016 was due to increased investment in leasehold improvements and office computer depreciation. Stock service and shareholder relations expense increase due to the Company becoming a public reporting company in December of 2016.

#### Interest Expense

We recorded $11,000 of interest expense, net for the six months ended June 30, 2017, compared to $77,000 for the same period in 2016. The decrease in interest expense of $66,000 was the result of a decrease of $2.9 million in convertible notes that were issued in 2014 and exchanged for Series B convertible preferred stock in December 2016.

#### Other Income (Expense), Net

We recorded $39,000 of other income, net, for the three months ended June 30, 2017, compared to $61,000 of other expense for the same period in 2016. The $100,000 net decrease in other expense was primarily due to the expense related to the year-over-year fair market value adjustment of our convertible promissory notes and losses on the extinguishment of said promissory notes.

### Liquidity and Capital Resources

Since our inception, we have incurred significant operating losses. We have generated limited revenue to date from research grants and licensing fees received under our former license agreement with Neogen. During the first six months of 2017, we began full scale marketing of our first product, ContraPest and we continue to develop other product candidates, which are in various phases of development. We have funded our operations to date primarily with proceeds from the sale of common stock and preferred stock, the issuance of convertible and other promissory notes and, to a lesser extent, payments received under research grants and pursuant to our former license agreement with Neogen. Through June 30, 2017, we had received net proceeds of $42.2 million from our sales of common stock and preferred stock and issuance of convertible and other promissory notes, and an aggregate of $1.6 million from licensing fees.

In the course of our research and development activities, we have sustained operating losses since our inception and expect such losses to continue for the near future. Our ultimate success depends upon the outcome of a combination of factors, including our ability to: (i) engage in successful research and development efforts; (ii) obtain ongoing regulatory approval of ContraPest and our other product candidates; (iii) achieve market acceptance and commercialization of ContraPest and our other products; (iv) successfully market our products and establish an effective sales force and marketing infrastructure to generate significant revenue; (v) retain and attract key personnel to develop, operate and grow our business; and (vi) successfully obtain additional financing as needed. As of June 30, 2017, we had an accumulated deficit of $68.4 million.

Based upon our current operating plan, we expect that our cash and cash equivalents and highly liquid, short term investments of approximately $5.6 million as of June 30, 2017, in combination with anticipated revenue, will be sufficient to fund our current operations for the foreseeable future. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect.

### Funding Requirements

We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance field studies of our product candidates in development. In addition, we incur additional costs associated with operating as a public company.

In particular, we expect to incur substantial and increased expenses as we:

- Continue the research and development of ContraPest and our other product candidates, including engaging in any necessary field studies;
- Seek ongoing regulatory approvals for ContraPest and our other product candidates;
- Scale up manufacturing processes and quantities to prepare for the commercialization of ContraPest and any other product candidates for which we receive regulatory approval;
- Establish an infrastructure for the sales, marketing and distribution of ContraPest and any other product candidates for which we may receive regulatory approval;
- Attempt to achieve market acceptance for our products;
- Expand our research and development activities and advance the discovery and development programs for other product candidates;
- Maintain, expand and protect our intellectual property portfolio; and
- Add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts and operations as a public company.

### Cash Flows

The following table summarizes our sources and uses of cash for each of the periods presented:

|  | Six Months Ended June 30, 2017 | 2016 |
| --- | ---: | ---: |
| Cash used in operating activities | $(5,636) | $(2,740) |
| Cash used in investing activities | (3,803) | (45) |
| Cash provided by financing activities | 287 | 5,960 |
| Net increase (decrease) in cash and cash equivalents | $(9,152) | $3,175 |

#### Operating Activities

During the six months ended June 30, 2017, operating activities used $5.6 million of cash, primarily resulting from our net loss of $7.0 million and by changes in our operating assets and liabilities of $0.6 million, partially offset by non-cash charges of $2.0 million. Our net loss was primarily attributed to research and development activities and our general and administrative expenses, as we generated limited product revenue during the period. Net cash used by changes in our operating assets and liabilities for the six months ended June 30, 2017 consisted primarily of a decrease in prepaid expenses of $145,000 and an increase in deferred rent of $13,000, offset by a net decrease in accrued expenses and accounts payable of $277,000, a net increase in inventories of $243,000, an increase in deposits of $217,000 and an increase of accounts receivable of $1,000. The net decrease in accrued expenses and accounts payable was primarily due to timing of expense occurrence and payables management, offset by our payment of the $1.0 million contract cancellation settlement accrual in January.

During the six months ended June 30, 2016, operating activities used $2.7 million of cash, primarily resulting from our net loss of $4.5 million, partially offset by non-cash charges of $2.0 million and by cash provided by changes in our operating assets and liabilities of $225,000. Our net loss was primarily attributed to research and development activities and our general and administrative expenses, as we generated limited research grant and licensing revenue during the period. Net cash provided by changes in our operating assets and liabilities for the six months ended June 30, 2016 consisted primarily of a $93,000 decrease in deferred revenue related to our license agreement with Neogen and a $132,000 decrease in accrued expenses and accounts payable. The decrease in accrued expenses and accounts payable was due to increased payments as a result of the receipt of cash raised in financing activities.

#### Investing Activities

For the six months ended June 30, 2017, we used $3.8 million in investing activities consisting of $2.9 million of purchases in securities to be held to maturity and $863,000 in purchases of property and equipment.

For the six months ended June 30, 2016, we used $45,000 of cash in investing activities, consisting of purchases of property and equipment.

#### Financing Activities

During the six months ended June 30, 2017, net cash used by financing activities was $287,000 as a result of $389,000 of proceeds from the issuance notes payable offset by payments of $39,000 related to notes payable and notes payable related party and $63,000 in payments of capital lease obligations.

During the six months ended June 30, 2016, net cash provided by financing activities was $6.0 million as a result of $6.2 million of proceeds from the issuance of shares of common stock in May 2016, $436,000 of proceeds received from our issuance of notes payable, $896,000 of proceeds received from the issuance of Series B convertible preferred stock, and $410,000 of proceeds received from the exercise of stock options, all of which were partially offset by payments of $1.4 related to the notes, payable, notes payable related party and convertible notes payable, $10,000 of capital lease repayments and $444,000 of deferred offering cost payments.

### Recent Developments

None

### Critical Accounting Policies and Significant Judgments and Estimates

Our financial statements are prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of our financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are described in more detail in Note 2 to our financial statements included elsewhere in this Quarterly Report on Form 10-Q, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.

### Revenue Recognition

We recognize revenue in accordance with the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”), Topic 605, *Revenue Recognition*. Accordingly, we recognize revenue from the commercial sale of products, licensing agreements and contracts to perform pilot studies when (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured.

We have generated revenue from a license agreement with a strategic partner pursuant to which we had granted to such partner the exclusive license in North America to manufacture, distribute and sell commercial control products based on our intellectual property, which includes ContraPest, for the later of 10 years or the expiration of the patent for ContraPest (if issued).

The license agreement was subsequently terminated on January 23, 2017.

When we receive non-refundable, upfront license fee payments for the exclusive rights to licensing our intellectual property, management determines if such license has stand-alone value. Since management determined that the license to our intellectual property did not have stand-alone value, we recognized revenue attributable to that license on a straight-line basis over the estimated related performance period. Any changes in the estimated period of performance will be accounted for prospectively as a change in estimate.

Our licensing agreement also provided for a future fixed amount of contingent milestone payments and contingent sales-based royalties to be received upon the achievement of milestone events. We recognize revenue that is contingent upon the achievement of a substantive milestone in its entirety in the period in which the milestone is achieved and the milestone payments are due and collectible. A milestone is considered substantive when the consideration payable to us for such milestone has all of the following characteristics: (1) there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved; (2) the event can only be achieved based in whole or part on either our performance or a specific outcome resulting from our performance; and (3) if achieved, the event would result in additional payments being due to us. In making this assessment in the future, we will consider all facts and circumstances relevant to the arrangement, including whether any portion of the milestone consideration is related to future performance or deliverables. In addition, we will account for sales-based royalties as revenue upon achievement of certain sales milestones.

### Stock-Based Compensation

We recognize compensation costs related to stock options granted to employees based on the estimated fair value of the awards on the date of grant, net of estimated forfeitures, in accordance with ASC Topic 718 — *Stock Compensation (“*ASC 718”). We estimate the grant date fair value of the awards, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model. The grant date fair value of stock-based awards is expensed on a straight-line basis over the vesting period of the respective award. We account for stock-based compensation arrangements with non-employees using a fair value approach. The fair value of these stock options is measured using the Black-Scholes option-pricing model reflecting the same assumptions as applied to employee options in each of the reported periods, other than the expected life, which is assumed to be the remaining contractual life of the option. The fair value of the stock options granted to non-employees is re-measured as the stock options vest and is recognized in the statements of operations and comprehensive loss during the period the related services are rendered.

We recorded stock-based compensation expense of approximately $1.9 million and $1.5 million for the six months ended June 30, 2017 and 2016, respectively. We expect to continue to grant stock options and other equity-based awards in the future, and to the extent that we do, our stock-based compensation expense recognized in future periods will likely increase.

The Black-Scholes option-pricing model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based awards. If we had made different assumptions, our stock-based compensation expense, net loss and loss per share of common stock could have been significantly different. Our assumptions are as follows:

- *Expected term.* The expected term represents the period that the stock-based awards are expected to be outstanding. Our historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of a lack of sufficient data. Therefore we estimate the expected term by using the simplified method, which calculates the expected term as the average of the time-to-vesting and the contractual life of the options.
- *Expected volatility.* Expected volatility is derived from the average historical volatilities of publicly traded companies within our industry that we consider to be comparable to our business over a period approximately equal to the expected term. We intend to continue to consistently apply this process using the same or similar public companies until a sufficient amount of historical information regarding the volatility of our own common stock price becomes available, or unless circumstances change such that the identified companies are no longer similar to us, in which case, more suitable companies whose share prices are publicly available would be utilized in the calculation.
- *Risk-free interest rate.* The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the expected term.
- *Expected dividend.* The expected dividend is assumed to be zero as we have never paid dividends and have no current plans to pay any dividends on our common stock.
- *Expected forfeitures.* We use historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period that the estimates are revised.

#### Significant Factors, Assumptions and Methodologies Used in Determining Fair Value of Our Common Stock

As noted above, we are required to estimate the fair value of the common stock underlying our stock-based awards when performing the fair value calculations using the Black-Scholes option-pricing model. Prior to our initial public offering in December 2016, in the absence of an active market for our common stock, we previously utilized methodologies in accordance with the framework of the American Institute of Certified Public Accountants’ Technical Practice Aid, *Valuation of Privately-Held Company Equity Securities Issued as Compensation* , to estimate the fair value of our common stock.

The assumptions underlying these valuations represent management’s best estimates, which involve inherent uncertainties and the application of management’s judgment. If we had made different assumptions than those used, the amount of our stock-based compensation expense, net income and net income per share amounts could have been significantly different. The fair value per share of our common stock for purposes of determining stock-based compensation expense is the closing price of our common stock as reported on the applicable grant date. The compensation cost that has been included in the statements of operations and comprehensive loss for all stock-based compensation arrangements is as follows:

|  | Three Months Ended June 30 2017 | 2016 | Six Months Ended June 30, 2017 | 2016 |
| --- | ---: | ---: | ---: | ---: |
| Research and development | $90 | $87 | $184 | $174 |
| General and administrative | 721 | 255 | 1,688 | 1,299 |
| Total stock-based compensation expense | $811 | $342 | $1,872 | $1,473 |

The intrinsic value of stock options outstanding as of June 30, 2017 is $5.9 million, of which $3.7 million and $2.2 million would have been related to stock options that were vested and unvested, respectively, at that date.

### Emerging Growth Company Status

The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected to “opt out” of this provision and, as a result, we intend to comply with new or revised accounting standards when they are required to be adopted by public companies that are not emerging growth companies.

## Controls and procedures

As filed, 1,388 characters.

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that the information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer (or Acting Principal Financial Officer, as the case may be), as appropriate, to allow timely decisions regarding required disclosure. Our management carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

There were no changes in our internal control over financial reporting during the three-month period ended June 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 3,907 characters.

Except as detailed below and disclosed in subsequently filed Quarterly Reports on Form 10-Q, there have been no material changes in the risk factors set forth in Part I, Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2016, as amended.

***Depending on the commercial success of ContraPest, we may require additional capital to fund our operations. Failure to obtain this necessary capital if needed may force us to delay, limit, or terminate our product development efforts or other operations.***

Developing product candidates, including conducting experiments and field studies, obtaining and maintaining regulatory approval and commercializing any products later approved for sale, is a time-consuming, expensive and uncertain process that takes years to complete. We expect our expenses to continue to increase in connection with our ongoing activities, particularly as we advance our commercialization activities. Based upon our current operating plan, we expect that our cash and cash equivalents and highly liquid, short term investments of approximately $5.6 million as of June 30, 2017, in combination with anticipated revenue, will be sufficient to fund our current operations for the foreseeable future. However, we plan to substantially expand our operations, and as a result of many factors, some of which may be currently unknown to us, our expenses may be higher than expected. Securing additional financing may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates, including ContraPest. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to:

- Significantly delay, scale back or discontinue the development or commercialization of our product candidates, including ContraPest;
- Seek strategic partners for the manufacturing, sales and distribution of ContraPest or any of our other product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; and
- Relinquish, or license on unfavorable terms, our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves.

The occurrence of any of the events described above would have a material adverse effect on our business, operating results and prospects and on our ability to develop our product candidates.

***If securities or industry analysts, or other sources of information, do not publish research, or publish inaccurate or unfavorable research or other information about our business, our stock price and trading volume could decline.***

The trading market for our common stock may depend on the research, reports and other information that securities or industry analysts, or other, third party sources of information, publish about us or our business. We do not have any control over these analysts or other, third party sources of information, and from time to time inaccurate or unfavorable research or other information about our business, financial condition, results of operations and stock ownership may be published. We cannot assure that analysts will cover us or provide favorable coverage. If one or more of the analysts who cover us downgrade our stock or change their opinion of our stock, our share price would likely decline. If one or more of these analysts cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our stock price or trading volume to decline. If incorrect or misleading information is disseminated publicly by third parties about us, our stock price could decline.

Filed Nov 7, 2017.
Source: SEC EDGAR, the filing index for accession 0001615774-17-006279. Last ingested by Listed: Nov 14, 2026, 18:52 ET. No prices; not investment advice.
